Literature DB >> 3080422

Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.

D C Stump, M Thienpont, D Collen.   

Abstract

Urokinase-related proteins were purified from 60-liter batches of human urine collected into the protease inhibitor aprotinin to prevent proteolytic degradation. Three homogeneous species were obtained by chromatography on zinc chelate-Sepharose, SP-Sephadex C-50, Sephadex G-100, benzamidine-Sepharose, and immunoadsorption on a murine anti-human urokinase monoclonal antibody. One urokinase-related protein with Mr 95,000 representing a complex of two-chain urokinase with an inhibitor accounts for about 70% of the total urokinase-related antigen in urine. Nucleophilic agents dissociate the complex into active two-chain urokinase and a protein with Mr 45,000-50,000 which is immunologically distinct from urokinase. Approximately 25% of the urinary urokinase-related antigen represents a single-chain molecule with Mr 54,000. This highly purified single-chain molecule was obtained with a yield of 5 micrograms/liter of urine. Only trace amounts (less than 5%) of the urokinase-related antigen were recovered as free two-chain urokinase. The urinary single-chain urokinase-related protein has no specific affinity for fibrin. It has a very low activity on Pyroglu-Gly-Arg-p-nitroanilide, a urokinase-specific synthetic substrate, but directly activates plasminogen following Michaelis-Menten kinetics with Km = 0.7 microM and kcat = 0.0011 S-1. The single-chain molecule is rapidly converted to active two-chain urokinase by plasmin. Active two-chain urinary urokinase has a very high amidolytic activity and activates plasminogen with Km = 60 microM and kcat = 1.4 S-1. It is concluded that the urokinase-related proteins in human urine consist of about 25% of single-chain urokinase (10-20 micrograms/liter) and of about 75% two-chain urokinase (40-50 micrograms/liter), the bulk of which is complexed to an inhibitor. Because even in freshly voided urine most of the urokinase-related antigen is already converted to two-chain urokinase, urine does not seem to be a suitable source for the large-scale purification of single-chain urokinase. In view of the very significant intrinsic plasminogen-activating properties of single-chain urokinase, it should not be considered to be a proenzyme form of urokinase. The dramatic differences of its kinetic constants from those of urokinase render the designation single-chain urokinase equally inadequate. Consequently, the designation "single-chain urokinase-type plasminogen activator" was recently adopted by the International Committee on Thrombosis and Haemostasis (Annual Meeting, San Diego, CA, July 13-14, 1985).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080422

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Disposable polymeric cryogel bioreactor matrix for therapeutic protein production.

Authors:  Era Jain; Ashok Kumar
Journal:  Nat Protoc       Date:  2013-04-04       Impact factor: 13.491

2.  Different Effects of Lipopolysaccharide on Plasminogen Activator Inhibitor-1 Production in Aortic Media in Vivo and in Culture.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

3.  A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 4.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

5.  Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system.

Authors:  M Laurell; A Christensson; P A Abrahamsson; J Stenflo; H Lilja
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

6.  Novel technique for the treatment of large subcapsular renal hematoma: combined use of percutaneous drainage and urokinase injection.

Authors:  Zhou Shen; Wenqiang He; Dong Liu; Feng Pan; Wencheng Li; Xiaomin Han; Bing Li
Journal:  Int Urol Nephrol       Date:  2014-04-13       Impact factor: 2.370

7.  Urokinase separation from cell culture broth of a human kidney cell line.

Authors:  Vibha Bansal; Pradip K Roychoudhury; Ashok Kumar
Journal:  Int J Biol Sci       Date:  2006-11-22       Impact factor: 6.580

8.  Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

9.  The urine urokinase concentration in end stage renal disease with acquired renal cyst.

Authors:  S Y Hong; D H Yang; B H Lee; E K Ki; K H Chung
Journal:  Korean J Intern Med       Date:  1991-07       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.